Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial

Bannerji, Rajat, Arnason, Jon E, Advani, Ranjana H · The Lancet Haematology · 2022